Intensity Modulated Radiotherapy (IMRT) for Anal Squamous Cell Cancer

Accuray June 20th, 2024

June 20th, 2024, 7am PDT | 10am EDT | 4pm CEST | 10pm HKT

Presenter: Marianna Alessandra Gerardi, M.D., Radiation Oncologist, European Institute of Oncology, Milan, Italy & Raffaella Cambria, MSc., Deputy Director of the Medical Physics Department, European Institute of Oncology, Milan, Italy 

Moderator: Barbara Alicja Jereczek-Fossa, M.D., Ph.D., Full Professor of Radiation Oncology, University of Milan, Italy. Head of the Department of Radiation Oncology, European Institute of Oncology, Milan, Italy


In the upcoming webinar, we will be discussing:

  • Guidelines for the treatment of non-metastatic anal cancer include the use of Intensity-modulated Radiotherapy (IMRT) or Volumetric Modulated Radiotherapy (VMAT) in association with chemotherapy.
  • The use of highly conformal treatment of anal cancer- This is attractive because of the large treatment volumes adjacent to the small bowel and bladder as well as exposure of the skin in the gluteal fold to high doses. The excellent oncological outcomes of radio-chemotherapy in anal cancers are historically associated with related side effects: hematologic toxicity, skin reaction, gastrointestinal and genitourinary toxicity.
  • The advantage of the TomoTherapy® System compared to the VMAT technique with a homogeneous Planning Target Volume (PTV) coverage, a simultaneous integrated boost (SIB) approach if indicated, and a daily Megavoltage CT imaging as part of image-guided radiotherapy (IGRT) to allow for bony and soft tissue alignment.

This webinar is pending approval from CAMPEP for 1 MPCEC hour and approved by ASRT for 1 category A credit.

DISCLAIMER: The statements and articles in the corporate news forum do not necessarily reflect the views of, and are not endorsed by ISRS. Please consult the specific corporate entity for relevant disclosures and restrictions related to these news features.